Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Array BioPharma and AstraZeneca have announced plans for two additional randomized Phase II trials for AZD6244.
Subscribe to our email newsletter
The trials, which will begin during the second half of 2008, will test AZD6244 (ARRY-886) in combination with a cytotoxic chemotherapeutic agent; one trial will be in melanoma patients and the other in non small cell lung cancer patients. These plans are based upon AZD6244’s activity as a single agent in previous monotherapy Phase II trials and on data from multiple preclinical studies.
AZD6244 is an anticancer drug in Phase II development in a range of tumors. It is a small molecule inhibitor that targets a key position in the Ras/Raf/MEK/ERK signalling pathway. This pathway is implicated in the development and progression of cancers.
John Yates, chief medical officer of Array, said: “We believe that AZD6244 holds promise for cancer patients and we look forward to the initiation of these additional Phase II trials.”